Novartis Will Spend $600 Mil. On Cell Culture-Derived Influenza Vaccine Facility
Swiss company to start construction on the first such manufacturing plant in the U.S. in 2007.
Swiss company to start construction on the first such manufacturing plant in the U.S. in 2007.